₹2110.0
-1.18% today
· 30d -11.65%
as of 2026-09-04
Price · Daily Candles
“Lupin's Q4 Profit Soars 87.72%, but FIIs and DIIs show stake shifts.”
Lupin delivered a robust Q4 2026, with net profit surging 87.72% YoY to ₹1469 Cr and revenue increasing 31.89% YoY to ₹7475 Cr. The company's annual net profit for FY26 reached ₹5355 Cr, a 61.98% increase over FY25, contributing to its strong 3-year net profit CAGR of 131.78%. Despite this, the stock trades at a TTM PE of 21.46, below its target mean of ₹2483.41, suggesting a potential undervaluation with a 135.7% margin of safety.
BULL CASE
+Lupin's Q4 FY26 net profit witnessed an impressive 87.72% YoY growth, reaching ₹1469 Cr.
+Annual revenue for FY26 grew 23.12% to ₹27958 Cr, with net profit increasing 61.98% to ₹5355 Cr.
+The company boasts a strong 3-year net profit CAGR of 131.78% and a 5-year net profit CAGR of 34.25%.
+Lupin is currently identified as 'undervalued' with a 135.7% margin of safety and a projected intrinsic value per share of ₹5761.46.
+ML predictions indicate strong ranks for sales growth (sales_1y_recent_2y: 0.852, sales_1y_rolling_4y: 0.872).
BEAR CASE
−Despite strong fundamentals, FII shareholding increased by 0.22% QoQ, while DII shareholding decreased by 0.26% QoQ in the latest quarter.
−The stock is trading near its 52-week high, only -3.35% off the peak of ₹2529.5, potentially limiting immediate upside.
−Recent 1-day and 1-week returns are negative at -2.13% and -2.05% respectively, despite a positive 1-month return of 7.46%.
−The company's OPM in Q4 FY26 was 34.49%, a slight increase of 10.41% from the prior year, but growth in operating profit was lower than net profit growth.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹8277 Cr
+32.04% YoY
NET PROFIT
₹1417 Cr
+16.01% YoY
OPM
30.69%
+2.23pp YoY
EPS
₹30.95
PE 21.46
Intrinsic value · DCF ₹3042.64 · Margin of safety +44.2% (undervalued) · FCF yield 5.67%
◇ Sector Position
Lupin's TTM PE of 21.46 and ROCE of 30.0% positions it competitively against peers like Cipla (PE 29.68, ROCE 25.09%) and Zydus Life (PE 22.27, ROCE 25.71%), but below Sun Pharma's higher valuation (PE 42.34).
PEERPEROCE %
LUPIN21.4630.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
70
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
STRONG
75
Valuation
REASONABLE
60
Growth
STRONG
88
Profitability
HIGH
95
Technicals
BEARISH
25
Risk
LOW
80
Key Stats
TTM PE
21.46
P/B
4.98
52W HIGH
₹2529.5
OFF HIGH
-16.58%
DIV YIELD
0.72%
MKT CAP
₹96900 Cr
◉ Active Signals
MACDBearish-3.3246
RSI(14)Bullish26.52
Street Consensus
37 analysts₹2483.41
mean target
Low ₹1800.0Now ₹2110.0High ₹2900.0
⧉ Strategy Fit 🔒